Skip to main content

Advertisement

Table 5 Predictors of clinical disease among participants with CBD at baseline

From: Long-term follow-up of beryllium sensitized workers from a single employer

Baseline Characteristics WITHOUT clinical CBD at follow-up
n = 15
WITH clinical CBD at follow-up
n = 7*
P value
Age in years (s.d.) 45.6 (9.27) 52.6 (12.0) 0.15
Race (% white) 93 100 0.48
Sex (%male) 73 86 0.52
History of hay fever, asthma or eczema % 47 57 0.65
Mean length from hire date to baseline evaluation, in years (s.d) 13.7 (5.9) 13.9 (9.4) 0.95
Period of beryllium exposure, in years (s.d) 18.6 (8.1) 16.6 (9.7) 0.61
Time from baseline to follow-up evaluation(s.d) 8.3 (2.9) 7.7 (4.4) 0.70
Baseline PFTs (% predicted (s.d.))    
FEV1 87.5 (16.3) 83.4 (18.3) 0.60
FVC 91.2 (12.2) 83.7 (9.3) 0.17
FEV1/FVC 95.9 (13.1) 92.9 (9.9) 0.60
DLCO 98.1 (23.9) 104.3 (22.0) 0.59
TLC 95.8 (17.2) 92.4 (9.0) 0.64
Follow-up Characteristics    
Smoking Status    
Nonsmoker % 40 29  
Ex smoker % 47 71 0.44
Current smoker % 13 0  
% still working at beryllium facility 27 14 0.52
BeLPT results *    
(+/+) 40 50  
(+/-) 33 33 0.89
(-/-) 27 17  
* result for 1 person was missing